Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M125,298Revenue $M18,676Net Margin (%)24.7Z-Score2.6
Enterprise Value $M130,203EPS $6.6Operating Margin %30.0F-Score5
P/E(ttm))25.9Cash Flow Per Share $6.7Pre-tax Margin (%)26.9Higher ROA y-yN
Price/Book5.010-y EBITDA Growth Rate %11.0Quick Ratio3.9Cash flow > EarningsY
Price/Sales6.45-y EBITDA Growth Rate %8.7Current Ratio4.2Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %15.5ROA % (ttm)7.4Higher Current Ratio y-yN
Dividend Yield %1.5Insider Buy (3m)0ROE % (ttm)21.0Less Shares Outstanding y-yN
Payout Ratio %36.0Shares Outstanding M761ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-09-30 Add1.39%$115.39 - $144.01
($130.57)
$ 164.7226%Add 194.44%1,325,000
AMGNJean-Marie Eveillard 2014-09-30 Buy 0.25%$115.39 - $144.01
($130.57)
$ 164.7226%New holding, 714178 sh.714,178
AMGNKen Fisher 2014-09-30 Add0.02%$115.39 - $144.01
($130.57)
$ 164.7226%Add 83.59%156,629
AMGNRuane Cunniff 2014-09-30 Buy $115.39 - $144.01
($130.57)
$ 164.7226%New holding, 1617 sh.1,617
AMGNVanguard Health Care Fund 2014-09-30 Reduce-0.32%$115.39 - $144.01
($130.57)
$ 164.7226%Reduce -12.75%7,022,755
AMGNJohn Hussman 2014-09-30 Reduce-0.23%$115.39 - $144.01
($130.57)
$ 164.7226%Reduce -50%25,000
AMGNJoel Greenblatt 2014-09-30 Reduce-0.01%$115.39 - $144.01
($130.57)
$ 164.7226%Reduce -72.9%2,693
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 164.7242%New holding, 450000 sh.450,000
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 164.7242%Add 85.28%60,335
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 164.7242%New holding, 9938 sh.9,938
AMGNKen Fisher 2014-06-30 Add0.01%$110.29 - $126.07
($115.72)
$ 164.7242%Add 71.02%85,316
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 164.7242%Reduce -66.67%50,000
AMGNKen Fisher 2014-03-31 Add0.01%$113.48 - $127.47
($120.95)
$ 164.7236%Add 754.67%49,887
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 164.7236%Add 37.87%32,565
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 164.7236%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 164.7236%Reduce -9.42%32,161,744
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 164.7236%Reduce -6.4%8,213,855
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 164.7236%Reduce -14.29%150,000
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 164.7236%Sold Out0
AMGNRay Dalio 2014-03-31 Sold Out -0.01%$113.48 - $127.47
($121.04)
$ 164.7236%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Jean-Marie Eveillard 2014-09-30714,1780.090.25New Buy
AMGN Ruane Cunniff 2014-09-301,61700New Buy
AMGN Daniel Loeb 2014-09-301,325,0000.172.1+194.44%
AMGN Ken Fisher 2014-09-30156,6290.020.05+83.59%
AMGN PRIMECAP Management 2014-09-3031,793,8734.184.8-0.19%
AMGN Mario Gabelli 2014-09-3059,9500.010.05-0.64%
AMGN Vanguard Health Care Fund 2014-09-307,022,7550.922.5-12.75%
AMGN Dodge & Cox 2014-09-3072,9070.010.01-15.08%
AMGN John Hussman 2014-09-3025,00000.3-50%
AMGN Joel Greenblatt 2014-09-302,69300-72.9%
AMGN Mark Hillman 2013-12-317,91201.4-1.95%
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2929.41view
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9728.72view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8345.99view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7747.37view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4549.14view
Piacquad DavidSVP, Business Development 2014-03-10Sell0$049.14view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.6930.02view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.5333.34view
Michael A KellyActing CFO 2014-01-10Sell0$033.34view
AMGEN INC10% Owner 2013-12-17Buy272,142$72253.14view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
    Amgen: Stronger Drug Portfolio with Acquisition Oct 28 2014 
    Daniel Loeb Comments on Amgen Inc Oct 22 2014 
    Third Point Q3 2014 Investor Letter Oct 22 2014 
    Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
    Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
    Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 


    More From Other Websites
    AstraZeneca/Amgen's Brodalumab Excels in Psoriasis Study Nov 26 2014
    4:01 pm Amgen and AstraZeneca (AZN) announce positive results from... Nov 25 2014
    Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of... Nov 25 2014
    Tiffany sparkles; Campbell Soup on the move; Sony's new plan Nov 25 2014
    Stock stumble after consumer confidence slips; GDP data revised up; Elsa and Disney overtake Barbie Nov 25 2014
    Astellas announces termination of Amgen-sponsored clinical studies of rilotumumab in gastric cancer... Nov 24 2014
    Amgen ends studies of gastric cancer drug Nov 24 2014
    Amgen ends studies of gastric cancer drug Nov 24 2014
    JANA Partners opens a stake in Amgen Nov 24 2014
    Amgen Ends Trials of Stomach-Cancer Therapy Nov 24 2014
    Amgen Surprise, Discontinues Stomach Cancer Drug Study Nov 24 2014
    Amgen ends trials of stomach-cancer therapy Nov 24 2014
    Amgen Stops Gastric-Cancer Drug Trials on Increase in Deaths Nov 24 2014
    Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced... Nov 24 2014
    Amgen scraps trials of drug for advanced stomach cancer Nov 24 2014
    Amgen Announces Termination Of All Amgen-Sponsored Clinical Studies Of Rilotumumab In Advanced... Nov 24 2014
    Motley Fool: Pundits pandering your wealth away Nov 22 2014
    Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Nov 21 2014
    Fighting kids' cancer... fixing a broken system Nov 21 2014
    New data fuels doctors' demands to rewrite U.S. heart guidelines Nov 21 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK